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Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high re-
currence rate and high mortality and morbidity. In this population, therefore, optimal anti-
coagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagu-
lant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy 
window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent 
blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation compo-
nent have been newly developed and tested in large clinical trials. Dabigatran, direct throm-
bin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great 
merits of rapid action time, short half-life, stable plasma concentration, and little drug in-
teraction. Recently, large randomized clinical trials and meta-analyses have been published 
to show the efficacy and safety of the new oral anticoagulants compared with warfarin. 
Based on the results from recent clinical trials, we revised recommendations to apply opti-
mal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic 
stroke or transient ischemic attack.
Keywords Atrial fibrillation; Secondary prevention; Stroke; Warfarin; New anticoagulant 
Guideline
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Introduction
Large nationwide multicenter stroke registry studies in Korea 
have shown an increase in cardioembolic stroke, which accounts 
for 20% of all ischemic strokes,1 and found that 19% of patients 
with ischemic stroke have atrial fibrillation.2 Cardioembolic 
stroke is also highly associated with severe neurological deficits, 
early and late embolic recurrences, and a high mortality. The 
most common cause of cardioembolic stroke is atrial fibrilla-
tion, the prevalence of which robustly increases with age.3 Risk 
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factors including congestive heart failure, old age, hypertension, 
diabetes mellitus, and previous stroke further increase the risk 
of stroke, and these risk factors are prevalent in patients with 
stroke. Therefore, anticoagulation is highly recommended for 
secondary stroke prevention in patients with nonvalvular atrial 
fibrillation without contraindications. Warfarin has traditionally 
been used for long-term therapy. A conventional oral anticoagu-
lant, warfarin confers its anticoagulant effect by inhibiting vita-
min K-dependent factors (II, VII, IX, X). However, warfarin 
use is challenging for physicians and patients on account of its 
narrow therapeutic window, the need for frequent blood test-
ing, its unstable anticoagulation effect, inter- and intra-individu-
al variability of action, and multiple drug and food interactions. 
Several oral anticoagulants targeting a specific coagulation fac-
tor have been developed recently. Dabigatran etexilate is rapidly 
converted into active dabigatran by plasma carboxyesterases 
and competitively and reversibly inhibits both thrombin activi-
ty and generation. Rivaroxaban, apixaban, and edoxaban are not 
prodrugs, and competitively and reversibly bind to the active 
site of factor Xa. The new anticoagulants have the advantages of 
rapid action, a short half-life, stable plasma concentration, and 
little drug interaction, and have been tested in large randomized 
clinical trials. The first edition of the secondary stroke preven-
tion guidelines for patients with atrial fibrillation was published 
in 2009, reflecting evidence published through June 30, 2007. 
However, large randomized clinical trials, subgroup analyses, 
and meta-analyses of the efficacy and safety of the new oral an-
ticoagulants (NOACs) have been published recently. Accord-
ingly, the guidelines writing committee revised the recommen-
dations for preventing secondary stroke in patients with atrial 
fibrillation. 
Previous guideline
The first edition of the secondary stroke prevention guidelines 
for patients with atrial fibrillation was published in 2009 and did 
not reflect evidence concerning the newly developed oral anti-
coagulants. The previous recommendations were as follows:
Warfarin treatment (INR 2.0-3.0) is recommended, unless 
contraindicated, in patients with ischemic stroke or transient 
ischemic attack coexisting with sustained or paroxysmal atrial 
fibrillation (Evidence level: Ia, Recommendation grade: A).
If anticoagulants cannot be used, aspirin can be used instead 
(Evidence level: Ia, Recommendation grade: A). The recom-
mended daily dose of aspirin is 325 mg. In Korea, a prescribable 
dose of 300 mg may be considered (Evidence level: IV, Recom-
mendation grade: GPP).
For the recurrence of ischemic stroke or transient ischemic at-
tack in atrial fibrillation patients already receiving adequate anti-
coagulation therapy, increasing the therapeutic target to INR 
2.5-3.5 or initiating combination therapy with antiplatelets may 
be considered (Evidence level: IV, Recommendation grade: C).
Methodology
Organization of the Korean Clinical Practice Guidelines 
Committee
Recommendations of the Korean Clinical Practice Guide-
lines (CPG) for Stroke are generated by summarizing foreign 
and Korean published evidence modified to take the Korean 
health care system into account. The first edition was published 
in 2009 and reflects evidence published through June 30, 2007. 
Since then, the Steering Committee has monitored new clinical 
evidence and selected topics requiring guidelines updates. The 
Steering Committee makes a final decision regarding guideline 
updates and appoints a Writing Committee chair for each of the 
following three areas: primary stroke prevention, acute stroke 
management, and secondary stroke prevention. Each chair or-
ganizes writing members by referring to their specialty with the 
approval of the Steering Committee. Under the supervision of 
each chair, the Writing Committee members search, compile, 
and evaluate new evidence and make recommendations for 
each topic. With the advent of new evidence for antithrombotic 
management in atrial fibrillation, the Steering Committee de-
cided to update the guideline for secondary stroke prevention in 
patients with atrial fibrillation and composed the Writing Com-
mittee. Disagreements among Writing Committee members 
were resolved by consensus. The Steering Committee reviewed 
the first draft and recommended revision if necessary. The Writ-
ing Committee’s revised draft was submitted, reviewed, and fi-
nally approved by the Steering Committee.
Evidence search process
The update process adheres to the international tool for the 
assessment of practice guidelines, the Appraisal of Guidelines 
for Research & Evaluation (AGREE II). The process of guide-
line development requires the documentation of all literature 
searches performed for the guideline revision. The search form 
to be completed by the Writing Committee includes items such 
as search duration, publication type, key words, search strategy, 
and database. For this revision, we searched articles from MED-
LINE/PubMed and the National Guideline Clearinghouse 
from July 2007 to May 2014 using the following key words: 
atrial fibrillation AND stroke OR transient attack AND antico-
agulant AND dabigatran OR rivaroxaban OR apixaban OR 
edoxaban AND warfarin AND stroke. Key words for exclusion 
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included catheter ablation, cardioversion, valve replacement 
surgery, and left atrial appendage closure. The studies were lim-
ited to randomized controlled trials, controlled clinical trials, 
meta-analyses, and guidelines. 
Evidence review and determination of recommendation 
level 
The Writing Committee reviewed all available studies meet-
ing the inclusion and exclusion criteria, and finally retrieved 8 
randomized controlled trials, 5 meta-analyses, and 4 subgroup 
analyses. The Writing Committee additionally reviewed 3 for-
eign updated guidelines including those of the European Society 
of Cardiology (2012),4 the American College of Cardiology/
American Heart Association (2014),5 and the American Stroke 
Association (2014).6 Then, the level of evidence and the grade 
of each recommendation were determined according to the for-
mat suggested by the US Agency for Healthcare Policy and Re-
search (currently the Agency for Healthcare Research and Qual-
ity, AHRG) in 1993 (Table 1). The level of evidence indicates 
the quality and strength of the cumulative scientific evidence, 
and the grade of recommendation implies how strongly a state-
ment is recommended. 
Revised recommendations (Table 2)
A full version of the updated proposal (in Korean) including 
detailed evidence is available in the Journal of the Korean Neu-
rological Association.
For patients who had an ischemic stroke or transient 
ischemic attack with persistent or paroxysmal nonvalvular 
atrial fibrillation, oral anticoagulant therapy with warfarin, 
dabigatran, rivaroxaban, or apixaban is recommended for 
the prevention of recurrent stroke if not contraindicated 
(Evidence level: Ia, Recommendation grade: A). The 
selection of an anticoagulation therapy should be 
individualized based on clinical characteristics, patient 
preference, and the potential for drug interactions 
Table 1. Guideline statement method of the US Agency for Healthcare Policy and Research
Level Type of evidence
Ia Evidence obtained from meta-analysis of randomized controlled trials.
Ib Evidence obtained from at least one randomized controlled trial.
IIa Evidence obtained from at least one well-designed controlled study without randomization.
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies.
IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities.
Grade Recommendation
A (evidence levels Ia, Ib) Required - at least one randomized controlled trial as part of the body of literature of overall good quality and consistency addressing specific
   recommendation.
B (evidence levels IIa, IIb, III) Required - availability of well conducted clinical studies but no randomized clinical trials on the topic of recommendation.
C (evidence level IV) Required - evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates absence 
   of directly applicable clinical studies of good quality.
GPP (good practice point) Recommended best practice based on the clinical experience of the guideline development group.
Table 2. Guidelines for the antithrombotic management of patients with atrial fibrillation and ischemic stroke or transient ischemic attack
1 For patients who had an ischemic stroke or transient ischemic attack with persistent or paroxysmal nonvalvular atrial fibrillation, oral anticoagulant therapy with 
   warfarin, dabigatran, rivaroxaban, or apixaban is recommended for the prevention of recurrent stroke if not contraindicated (Evidence level: Ia, Recommendation 
   grade: A). The selection of an anticoagulation therapy should be individualized based on clinical characteristics, patient preference, and the potential for drug 
   interactions (Recommendation grade: GPP). (New recommendation)
2 For patients treated with warfarin, adjusted-dose warfarin therapy targeting an INR of 2.0¬.3.0 is recommended (Evidence level: Ia, Recommendation grade: A). 
   (Modified recommendation)
3 For patients treated with new oral anticoagulants (NOACs), renal function should be evaluated prior to the initiation of a NOAC. In patients with severe renal 
   impairment, dabigatran, rivaroxaban, and apixaban are not recommended (Evidence level: III, Recommendation grade: B). (New recommendation)
4 For patients who suffered a cardioembolic ischemic stroke or transient ischemic attack despite adequate anticoagulation with warfarin, warfarin therapy targeting 
   a higher INR, the addition of an antiplatelet agent, or a switch to dabigatran, rivaroxaban, or apixaban can be considered (Evidence level: IV, Recommendation 
   grade: C). (Modified recommendation)
5 Dabigatran, rivaroxaban, or apixaban can be considered in patients with nonvalvular atrial fibrillation who have a history of intracranial hemorrhage or are at a high risk 
   of intracranial hemorrhage (Evidence level: III, Recommendation grade: B). (New recommendation)
6 For patients with an ischemic stroke or transient ischemic attack and atrial fibrillation who cannot use oral anticoagulants, an antiplatelet agent should be considered 
   (Evidence level: I, Recommendation grade: A). Aspirin monotherapy or aspirin plus clopidogrel combination therapy can be considered, and the selection of antiplatelet 
   therapy should be based on balancing the risks of ischemic events and major bleedings (Evidence level: Ib, Recommendation grade: A). (Modified recommendation)
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(Recommendation grade: GPP). (New recommendation)
The most notable change in the current revised guidelines is 
the recommendation of both NOACs and warfarin. The Ia evi-
dence level for warfarin therapy in patients who suffered an isch-
emic stroke or transient ischemic attack with nonvalvular persis-
tent or paroxysmal atrial fibrillation was assigned on the basis of 
the European Atrial Fibrillation Trial (EAFT) of warfarin for sec-
ondary stroke prevention7 and on an individual patient pooled 
analysis of 5 randomized controlled trials that included some 
secondary prevention subjects.8 For NOACs, large randomized 
controlled trials demonstrated that the efficacy and safety of dab-
igatran, rivaroxaban, apixaban, and edoxaban were at least non-
inferior or superior to those of warfarin or aspirin.9-14 In subgroup 
analyses, the relative efficacy and safety of NOACs versus warfa-
rin did not differ between patients with/without a prior history 
of stroke or transient ischemic attack.15-18 Moreover, the benefits 
of dabigatran were uniform across Asian and non-Asian sub-
groups.19 Despite the limitations inherent in combining hetero-
geneous trials testing different NOACs, 4 meta-analyses of over-
all trial populations and one meta-analysis that exclusively fo-
cused on patients with a prior history of stroke or transient isch-
emic attack consistently demonstrated that NOACs were superi-
or to warfarin for stroke prevention as well as intracranial bleed-
ing.20-24 While dabigatran, rivaroxaban, and apixaban were ap-
proved by the Korean Food and Drug Administration for stroke 
prevention in patients with nonvalvular atrial fibrillation, edoxa-
ban has yet to be approved and was therefore excluded from this 
guideline statement. A Ia evidence level and A recommendation 
grade were assigned to NOACs for secondary stroke prevention 
in patients with atrial fibrillation. However, due to the lack of tri-
als directly comparing NOACs, selection among the new antico-
agulants was recommended at the GPP level to be dependent on 
patient characteristics including thrombosis risk, mechanism, co-
morbidities, patient preference, and the potential for drug inter-
actions.
For patients treated with warfarin, adjusted-dose 
warfarin therapy targeting an INR of 2.0-3.0 is 
recommended (Evidence level: Ia, Recommendation 
grade: A). (Modified recommendation)
The Ia evidence level and A recommendation grade were as-
signed based on the EAFT treatment protocol targeting an INR 
of 2.0-3.07 and pooled data from 5 randomized controlled trials.8 
For patients treated with NOACs, renal function should 
be evaluated prior to the initiation of a NOAC. In 
patients with severe renal impairment, dabigatran, 
rivaroxaban, and apixaban are not recommended 
(Evidence level: III, Recommendation grade: B). (New 
recommendation)
NOACs are mainly or partly eliminated by renal excretion. 
Therefore, renal function should be assessed prior to NOAC 
use. Renal dysfunction criteria for clinical trial enrollment are 
variable across different NOACs. The RE-LY9 and ROCKET-
AF trials11 excluded patients with severe renal dysfunction (CrCl 
< 30 mL/min), whereas the AVERROES12 and ARISTOTLE 
trials13 excluded patients with a serum Cr > 2.5 mg/dL or CrCl 
< 25 mL/min. In addition, regulatory approval for the use of 
NOACs in patients with renal dysfunction varies across coun-
tries. Taken together, these data indicate that NOACs should be 
selected very cautiously in cases of severely impaired renal func-
tion. This statement was given a III evidence level and B recom-
mendation grade owing to the lack of well-designed studies. 
For patients who suffered a cardioembolic ischemic 
stroke or transient ischemic attack despite adequate 
anticoagulation with warfarin, warfarin therapy targeting a 
higher INR, the addition of an antiplatelet agent, or a 
switch to dabigatran, rivaroxaban, or apixaban can be 
considered (Evidence level: IV, Recommendation grade: C). 
(Modified recommendation)
There are no validated data to serve as a basis for recommend-
ing antithrombotics for patients who had a cardioembolic isch-
emic stroke or transient ischemic attack despite adequate antico-
agulation with warfarin. However, this is a scenario frequently 
encountered in clinical practice and we therefore provide a rec-
ommendation on the basis of expert consensus. For these pa-
tients, we recommend considering one of the following: a high-
er INR target, the addition of antiplatelet therapy, or a switch to 
dabigatran, rivaroxaban, or apixaban. The assigned evidence lev-
el and recommendation grade were IV and C, respectively. 
Dabigatran, rivaroxaban, or apixaban can be considered 
in patients with nonvalvular atrial fibrillation who have a 
history of intracranial bleeding or are at a high risk of 
intracranial bleeding (Evidence level: III, Recommendation 
grade: B). (New recommendation)
No randomized controlled trials or experimental studies di-
rectly tested the efficacy and safety of any antithrombotic thera-
py for patients with nonvalvular atrial fibrillation who have a his-
tory of intracranial bleeding or are at a high risk of intracranial 
bleeding. However, a reduction of hemorrhagic stroke with dabi-
gatran, rivaroxaban, and apixaban versus warfarin was demon-
strated in randomized clinical trials9-14 and meta-analyses20-24 and 
further supported by subgroup analyses of patients with a histo-
ry of stroke or transient ischemic attack.15-18 
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For patients with an ischemic stroke or transient 
ischemic attack and atrial fibrillation who cannot use 
oral anticoagulants, an antiplatelet agent should be 
considered (Evidence level: I, Recommendation grade: 
A). Aspirin monotherapy or aspirin plus clopidogrel 
combination therapy can be considered, and the 
selection of antiplatelet therapy should be based on 
balancing the risks of ischemic events and major 
bleedings (Evidence level: Ib, Recommendation grade: 
A). (Modified recommendation)
Although the efficacy of antiplatelet therapy is greatly inferior 
to that of anticoagulant therapy, a meta-analysis showed that 
compared with placebo, antiplatelet therapy significantly reduced 
the risk of stroke.25 Therefore, antiplatelet therapy is recommend-
ed for patients who cannot use oral anticoagulation therapy. The 
ACTIVE-A trial suggested that the addition of clopidogrel to as-
pirin was more effective than aspirin monotherapy, but increased 
the risk of major hemorrhage.26 Therefore, our recommendation 
is that combination therapy with aspirin and clopidogrel can be 
considered while balancing the risk of ischemic events and major 
bleedings in individual patients with a Ib evidence level and A 
recommendation grade.
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